These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3651150)

  • 1. A systematic approach to heparin administration for pediatric hemodialysis.
    Paulsen JT; Kersting GL
    ANNA J; 1987 Aug; 14(4):265-8, 277. PubMed ID: 3651150
    [No Abstract]   [Full Text] [Related]  

  • 2. WBPTT and ACT clotting time methods for use in hemodialysis.
    Anderson R; Steeno M
    AANNT J; 1982 Apr; 9(2):27-30. PubMed ID: 6917761
    [No Abstract]   [Full Text] [Related]  

  • 3. [The resistance of activated partial thromboplastin time to heparin infusion during hemodialysis].
    Camici M; Sagripanti A; Barsotti G; Baicchi U; Evangelisti L; Morelli E; Giovannetti S
    Minerva Med; 1995 Sep; 86(9):353-5. PubMed ID: 7501225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin and prostacyclin.
    Camici M; Evangelisti L
    Angiology; 1989 Apr; 40(4 Pt 1):294-9. PubMed ID: 2650580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Individual dosage schedule of heparin therapy in chronic hemodialysis by analytic studies of blood coagulation].
    Gläser V; Anstadt M
    Z Urol Nephrol; 1990 Mar; 83(3):133-40. PubMed ID: 2356667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients.
    Low CL; Bailie G; Morgan S; Eisele G
    Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin].
    Vukusich A; Avalos C; Orellana G; Cifuentes C; Rivas J; Calderón F
    Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experiences with minimal intermittent heparinization in chronic dialysis patients].
    Kovác A; Hünicke G; Bierwisch H
    Z Urol Nephrol; 1980 May; 73(5):353-9. PubMed ID: 7456802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
    Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
    Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A low molecular heparin fraction as an anticoagulant during hemodialysis.
    Ljungberg B
    Clin Nephrol; 1985 Jul; 24(1):15-20. PubMed ID: 4017295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin-free hemodialysis in chronic patients for temporary management of conditions with a high risk of bleeding].
    Stradtmann H; Förster S; Jalinski W
    Z Urol Nephrol; 1988 Jul; 81(7):449-53. PubMed ID: 3176720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding.
    Lee KB; Kim B; Lee YH; Yoon SJ; Kang WH; Huh W; Kim DJ; Oh HY; Kim YG
    Nephron Clin Pract; 2004; 97(1):c5-10. PubMed ID: 15153761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
    Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heparin dosage in chronic hemodialysis (author's transl)].
    Vogel GE; Hansen W; Goldmann FL; Kopp KF
    Med Klin; 1977 Oct; 72(40):1617-23. PubMed ID: 916946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase can reduce heparin dose in patients with hypercoagulable states during hemodialysis.
    Ren W; Wei F; Sha Y; Wang Q; Xie L
    Ren Fail; 2015 May; 37(4):646-51. PubMed ID: 25687383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease.
    Kaneva K; Bansal V; Hoppensteadt D; Cunanan J; Fareed J
    Clin Appl Thromb Hemost; 2013; 19(4):449-52. PubMed ID: 23463188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inadvertent postdialysis anticoagulation due to heparin line locks.
    Pepper RJ; Gale DP; Wajed J; Bommayya G; Ashby D; McLean A; Laffan M; Maxwell PH
    Hemodial Int; 2007 Oct; 11(4):430-4. PubMed ID: 17922740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.